Barclays
IOVA icon

Barclays’s Iovance Biotherapeutics IOVA Stock Holding History

Barclays’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,000
Closed -$111K – 6292
2019
Q4 		$111K Buy
+4,000
New +$91K ﹤0.01% 5424

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Barclays's IOVA Position: Q1 2026 in Review

Barclays reduced its Iovance Biotherapeutics (IOVA) stake by 94% in Q1 2026, selling an estimated $3.4M and leaving 63,180 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

Barclays first reported a position in IOVA in Q2 2015 and has held it in 43 quarters since. The position peaked at $6.8M in Q4 2023. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Barclays held 63,180 shares of Iovance Biotherapeutics worth $222K as of Q1 2026.
  • Barclays sold 1,063,977 Iovance Biotherapeutics shares in Q1 2026, an estimated $3.4M.
  • Iovance Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3634 holding.
  • Barclays first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 43 quarters since.
  • Barclays's Iovance Biotherapeutics position peaked at $6.8M in Q4 2023.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.